BrainsWay (NASDAQ:BWAY – Get Free Report) had its price target raised by Oppenheimer from $5.50 to $6.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 26.05% from the stock’s current price.
A number of other brokerages have also recently commented on BWAY. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of BrainsWay in a research report on Friday, September 22nd. Raymond James cut shares of BrainsWay from an “outperform” rating to a “market perform” rating in a research report on Thursday.
BrainsWay Stock Up 1.9 %
BrainsWay (NASDAQ:BWAY – Get Free Report) last issued its quarterly earnings results on Wednesday, November 15th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. The business had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $7.70 million. BrainsWay had a negative net margin of 28.45% and a negative return on equity of 18.95%. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. Research analysts expect that BrainsWay will post -0.36 earnings per share for the current fiscal year.
Hedge Funds Weigh In On BrainsWay
A number of institutional investors and hedge funds have recently made changes to their positions in BWAY. Advisor Group Holdings Inc. boosted its position in shares of BrainsWay by 130.5% during the 1st quarter. Advisor Group Holdings Inc. now owns 4,552 shares of the company’s stock worth $40,000 after purchasing an additional 2,577 shares in the last quarter. Wasatch Advisors Inc. increased its stake in BrainsWay by 4.7% in the 1st quarter. Wasatch Advisors Inc. now owns 1,285,631 shares of the company’s stock valued at $11,198,000 after buying an additional 58,172 shares during the last quarter. State Street Corp increased its stake in BrainsWay by 3.7% in the 1st quarter. State Street Corp now owns 162,609 shares of the company’s stock valued at $1,416,000 after buying an additional 5,846 shares during the last quarter. Millennium Management LLC purchased a new stake in BrainsWay in the 2nd quarter valued at about $73,000. Finally, Jane Street Group LLC purchased a new stake in BrainsWay in the 4th quarter valued at about $38,000. Institutional investors own 30.76% of the company’s stock.
BrainsWay Company Profile
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
- Five stocks we like better than BrainsWay
- The How and Why of Investing in Gold Stocks
- 3 large caps with red hot RSIs with upside
- Following Congress Stock Trades
- Johnson Controls International: Nothing but upside for investors
- Trading Stocks: RSI and Why it’s Useful
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.